Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

26.61 4.81

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

24.58

Maximum

25.57

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+27.34% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

826M

2.9B

Előző nyitás

21.8

Előző zárás

26.61

Hangulat hírek alapján

By Acuity

50%

50%

156 / 340 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 18. 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

2026. aug. 18. 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

2026. aug. 18. 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

2026. aug. 18. 23:51 UTC

News
Social Media
Event

La-Z-Boy Inc reported a net loss of $2.29 million and lowered its revenue guidance, leading shares to trade lower in after-market hours.

2026. aug. 18. 23:51 UTC

News

JBS N.V. has proposed to acquire an 18% stake in Pilgrim's Pride, offering 2.086 shares per Pilgrim's Pride share. Shares are higher in after-market trading.

2026. aug. 18. 23:46 UTC

News

Blue Owl Capital shares are lower in after-market hours following a recent bond issuance of $400 million by its affiliate. Analysts estimate fair value at $12.38.

2026. aug. 18. 23:41 UTC

News
Social Media

UGI Corp shares rose in after-market trading on news of KKR's unsolicited $9 billion acquisition proposal, valuing the company at about $42.50 per share.

2026. aug. 18. 23:41 UTC

News

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

2026. aug. 18. 23:36 UTC

News

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

2026. aug. 18. 23:36 UTC

News
Correlated Moves

SPDR Gold Shares trade lower in after-market hours as Indonesia holds rates steady, while rising crude oil prices may affect inflation and market dynamics.

2026. aug. 18. 23:21 UTC

News
Correlated Moves

Silver is trading lower in after-market hours, reflecting a decline alongside the United States Copper Index Fund. Silver remains above its 20-day moving average.

2026. aug. 18. 23:21 UTC

Event
News

Jack Henry & Associates projects fiscal 2027 GAAP sales of $2.684 billion to $2.709 billion, exceeding analyst estimates, as shares rise in after-market hours.

2026. aug. 18. 23:21 UTC

News

Evolution Petroleum shares are lower in after-market trading following a public offering announcement to fund a $16 million acquisition in the Midland Basin.

2026. aug. 18. 23:21 UTC

News

Norfolk Southern completed its Living Shoreline project and advanced in after-market trading, showing strength above its 20-day moving average.

2026. aug. 18. 23:21 UTC

News

Enovix Corporation shares rise in after-market hours as executives reassure investors and reaffirm Q3 2026 revenue guidance of $9.0 million to $10.0 million.

2026. aug. 18. 23:11 UTC

Correlated Moves
News

Photronics Inc is facing a potential securities fraud lawsuit, contributing to a decline in after-market trading. The Russell 2000 Index also showed a slight decrease.

2026. aug. 18. 23:06 UTC

News
Social Media

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

2026. aug. 18. 23:02 UTC

News
Correlated Moves
Social Media

Price target raised to $1,250; shares lower in after-market.

2026. aug. 18. 23:01 UTC

News

Toll Brothers reported third-quarter earnings of $280.1 million, exceeding expectations. Shares are trading higher in after-market hours following the results.

2026. aug. 18. 23:01 UTC

News

Automatic Data Processing shares are lower in after-market trading despite a rebound in U.S. private-sector hiring, amid rising U.S. Treasury yields.

2026. aug. 18. 23:01 UTC

News
Social Media

Mercury Systems shares fell after reporting a decline in net income to $798,000 and missing adjusted EPS estimates by $0.02 in after-market trading.

2026. aug. 18. 23:01 UTC

News

Union Pacific shares are higher in after-hours trading as the Surface Transportation Board advances merger discussions with Norfolk Southern, boosting investor sentiment.

2026. aug. 18. 23:01 UTC

News
ETF Constituents

The Vanguard Growth ETF is higher in after-market trading, supported by gains in META and AMZN, despite broader market pressures from inflation and geopolitical tensions.

2026. aug. 18. 23:01 UTC

News
Social Media
Event

Keysight Technologies reported third-quarter revenue of $1.846 billion, exceeding expectations. Shares rose in after-market trading following the strong earnings and raised guidance.

2026. aug. 18. 23:01 UTC

News

Blue Owl Capital shares are higher in after-market hours as Blue Owl Technology Finance prices $400 million in bonds, exceeding its $200 million target.

2026. aug. 18. 23:01 UTC

News
Social Media

Dell Technologies shares are lower in after-market trading amid broader market pressures and rising U.S. Treasury yields ahead of its September 1 earnings call.

2026. aug. 18. 23:01 UTC

News

Kennametal Inc appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, prompting shares to advance in after-market trading.

2026. aug. 18. 22:02 UTC

News

Curtiss-Wright Corp announced a $100 million expansion of its share repurchase program, raising total buybacks to $260 million for 2026. Shares are higher in after-market trading.

2026. aug. 18. 21:03 UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

2026. aug. 18. 21:01 UTC

News

Cinemark Holdings Inc. shares rise after *Spider-Man: Brand New Day* becomes the highest-grossing domestic film in the company's history within three weeks of release.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

27.34% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 32.65 USD  27.34%

Magas 45 USD

Alacsony 21.6 USD

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

3

Vétel

1

Tartás

0

Eladás

Hangulat

By Acuity

156 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat